Skip to main content
Home > eLearning > White Papers
eLearning Center
The content listed below is submitted by our sponsors.
Featured White Paper

CFO’s Guide to Low-Cost, Non-Dilutive Revenue Interest Financing (RIF) Capital

Sponsored By: Houlihan Lokey
Posted on September 16, 2016

As the cost of capital of non-dilutive Royalty and Revenue Interest Financing (RIF) for commercial-stage biotech, pharma, medical device, and diagnostics companies with market-leading, differentiated products has fallen to capped mezzanine levels, this form of financing has now been adopted by small, medium, and large public and private companies. With an absence of financial covenants and restrictive operating covenants and the ability to refinance at no premium to a negotiated capped cost of capital, RIF has become an attractive, mainstream financing tool. In this white paper, Houlihan Lokey’s Lionel Leventhal and Fedora Baloiu provide a briefing on what the most accomplished life science CFOs already understand.

Biopharma Operational Scale Up for First Product Launch: Planning for Successful Execution in Challenging Times

By: L.E.K. Consulting
Posted on July 14, 2016

The time it takes to go from an R&D-focused to a fully integrated drug company can be very quick, which means you have to be prepared to make difficult choices about scaling up the enterprise and customizing the operational model to ensure a successful first product launch. How demanding will it be? Should you retain partial or full ownership of your first product? What is the optimal commercial model for your product? How do you develop the overall enterprise model? In this Executive Insights white paper L.E.K.’s Pierre Jacquet, David Barrow, Peter Rosenorn and Delia Silva provide perspectives on lessons learned from biopharma companies that have successfully transformed into commercial organizations.


Diagnostics for Superbugs: A Lynchpin for Turning the Tables on this Global Scourge

By: L.E.K. Consulting
Posted on July 14, 2016

The alarming rate at which antibiotic-resistant superbugs are growing will cost approximately $3 trillion by 2050, with some virulent pathogens evolving past the point of treatment with current drugs. While several interrelated barriers contribute to low returns on antibiotics, there are bigger issues with novel, more targeted antibiotics and the lack of rapid precision diagnostics (Dx) to target antibiotic use more effectively. In this Executive Insights white paper L.E.K.’s Jonathan Kfoury and Alex Vadas outline the complex challenges faced by life sciences and healthcare organizations and how to navigate the path forward.


In Vitro Diagnostics

By: BioVox
Posted on May 23, 2016

BioVox.eu, a life sciences communication platform, created a white paper on In Vitro Diagnostics. Download the report that discusses the challenges and opportunities of IVD in Europe and US with industry experts. The White Paper also features an overview of the Belgian diagnostics ecosystem, a hot spot for IVD technology and R&D, monitored closely by big IVD players.


Amyotrophic Lateral Sclerosis (ALS) Collection

Sponsored by: Cytokinetics and Brainstorm Cell Therapeutics
Posted on May 6, 2016

Download the following report that highlights BioCentury's coverage of clinical and regulatory events in amyotrophic lateral sclerosis (ALS), in addition to outlining the current state of the ALS drug development pipeline, partnering, and financial environments. The report also features case studies on two companies in the ALS space.


Lost in Translation

By: BioCentury
Posted on May 9, 2016

BioCentury is finding a fundamental disconnect in Europe. Pools of investment capital are forming around academic science, even as the money needed to get those discoveries into and through the clinic continues to lag. At the scene-setting Bio€quity Europe Face-Off, top Editors Susan Schaeffer of BioCentury and Simone Fishburn of BioCentury Innovations documented this conundrum and debated with the audience whether it could thwart European biotech's global ambitions.


Real World Evidence in Life Sciences: What Happens After Clinical Trials?

By: SAS
Posted on January 13, 2016

Life sciences companies are being asked by regulators, payers, providers and patients to prove therapies measure up to their promise in the real world. That desire actually creates an incredible opportunity to gain insights from tens of thousands of patients versus the limited population of a clinical trial because transforming HEOR data into real-world evidence gives a clearer picture of product safety and effectiveness, economics and value in actual use. This paper discusses: how using advanced analytics helps bridge the data-to-evidence gap, allowing integration and management of diverse data sources; fit-for-purpose analytical applications; scalable, high-performance computing power; and the option to move to the cloud.


Making Real-World Evidence Real

By: SAS
Posted on January 5, 2016

Life sciences companies are being asked by regulators, payers, providers and patients to prove therapies measure up to their real-world promise. Transforming HEOR data into real-world evidence gives a clear picture of product safety and effectiveness, economics and value in actual use. This paper discusses how using advanced analytics technology will help bridge the data-to-evidence gap, allowing integration and management of diverse data sources; fit-for-purpose analytical applications; scalable, high-performance computing power; and the option to move to the cloud.